Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | HTT | P42858 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 1/20 | 0.69 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.69 |
| ▸ | NAMPT | P43490 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | CASR | P41180 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28566662 | 0.91 | RAB9A (0.66) | MTORRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL30050253 | 0.91 | RAB9A (0.66) | MTORRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL11617698 | 0.87 | NAMPT (0.82) | MTORRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL14433810 | 0.86 | RAB9A (0.78) | MTORRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL28414184 | 0.85 | KMT2A (1.00) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL14860031 | 0.84 | MTOR (0.72) | MTORRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL2831462 | 0.84 | NPC1 (0.77) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL12218554 | 0.83 | KMT2A (0.95) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL8177097 | 0.83 | RAB9A (0.72) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL27953145 | 0.83 | RAB9A (0.72) | MTORRAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
| US-6124288-A | Xanthines and their therapeutic use | DARWIN DISCOVERY, LTD. (GB) | 2000-09-26 | — | — | US | disclosed |
| US-5821366-A | Xanthines and their therapeutic use | CHIROSCIENCE LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0825993-A1 | XANTHINES AND THEIR THERAPEUTIC USE | Chiroscience Limited (GB) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036638-A1 | XANTHINES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | MTOR 4056/4885RAB9A 3102/4885MEN1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.